Goldman Hires Former UK Prime Minister Sunak as a Senior Adviser
Sunak, who served as prime minister from October 2022 to July 2024, will work with leaders across New York-based Goldman to advise clients globally on a range of topics, 'sharing his unique perspectives and insights on the macroeconomic and geopolitical landscape,' Chief Executive Officer David Solomon said in a statement Tuesday.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Sampo plc's share buybacks 12 August 2025
Sampo plc, stock exchange release, 13 August 2025 at 8:30 am EEST Sampo plc's share buybacks 12 August 2025 On 12 August 2025, Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows: Sampo plc's share buybacks Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares* Market (MIC Code) 4,620 9.79 AQEU 129,455 9.77 CEUX 40,230 9.77 TQEX 156,075 9.76 XHEL TOTAL 330,380 9.76 * rounded to two decimals On 6 August 2025, Sampo announced a share buyback programme of up to a maximum of EUR 200 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 7 August 2025, is based on the authorisation granted by Sampo's Annual General Meeting on 23 April 2025. After the disclosed transactions, the company owns in total 1,316,278 Sampo A shares representing 0.05 per cent of the total number of shares in Sampo plc. Details of each transaction are included as an appendix of this announcement. On behalf of Sampo plc, Morgan Stanley For further information, please contact: Sami TaipalusHead of Investor Relations tel. +358 10 516 0030 Distribution: Nasdaq Helsinki Nasdaq Stockholm Nasdaq Copenhagen London Stock Exchange FIN-FSA The principal media Attachment Sampo_share_buyback_12_08_2025
Yahoo
14 minutes ago
- Yahoo
European Value Stocks: STMicroelectronics And Two More Priced Below Estimated Worth
As European markets experience a boost from strong corporate earnings and optimism surrounding geopolitical tensions, investors are increasingly on the lookout for stocks that are trading below their intrinsic value. In this environment, identifying undervalued stocks like STMicroelectronics can offer potential opportunities for those seeking to capitalize on discrepancies between market price and estimated worth. Top 10 Undervalued Stocks Based On Cash Flows In Europe Name Current Price Fair Value (Est) Discount (Est) Sparebank 68° Nord (OB:SB68) NOK178.50 NOK354.42 49.6% Robit Oyj (HLSE:ROBIT) €1.135 €2.25 49.5% Pluxee (ENXTPA:PLX) €17.50 €34.12 48.7% Norconsult (OB:NORCO) NOK44.70 NOK87.62 49% Lingotes Especiales (BME:LGT) €6.00 €11.69 48.7% Hanza (OM:HANZA) SEK111.00 SEK219.77 49.5% Exel Composites Oyj (HLSE:EXL1V) €0.383 €0.76 49.6% Atea (OB:ATEA) NOK141.40 NOK282.51 49.9% Aquila Part Prod Com (BVB:AQ) RON1.48 RON2.92 49.4% ams-OSRAM (SWX:AMS) CHF10.59 CHF20.83 49.1% Click here to see the full list of 193 stocks from our Undervalued European Stocks Based On Cash Flows screener. Let's explore several standout options from the results in the screener. STMicroelectronics Overview: STMicroelectronics N.V. is a company that designs, develops, manufactures, and sells semiconductor products across Europe, the Middle East, Africa, the Americas, and the Asia Pacific with a market cap of approximately €20.03 billion. Operations: The company's revenue segments include Power and Discrete Products at $2.76 billion and Analog, MEMS & Sensors Group at $4.22 billion. Estimated Discount To Fair Value: 42.7% STMicroelectronics is trading at €22.42, significantly below its estimated fair value of €39.15, suggesting it may be undervalued based on cash flows. Despite a recent net loss of US$97 million in Q2 2025, the company's earnings are forecast to grow substantially at 34.9% annually over the next three years, outpacing the French market's growth rate. Recent strategic moves include acquiring NXP's MEMS sensors business and expanding capabilities through a license agreement with Metalenz for advanced metasurface optics production. Upon reviewing our latest growth report, STMicroelectronics' projected financial performance appears quite optimistic. Click to explore a detailed breakdown of our findings in STMicroelectronics' balance sheet health report. Lerøy Seafood Group Overview: Lerøy Seafood Group ASA is involved in the production, processing, marketing, sales, and distribution of seafood products and has a market cap of NOK29.46 billion. Operations: The company's revenue segments include Farming at NOK14.41 billion, Wildcatch at NOK2.61 billion, and VAP, Sales and Distribution at NOK30.66 billion. Estimated Discount To Fair Value: 47.1% Lerøy Seafood Group, trading at NOK 49.48, is significantly below its estimated fair value of NOK 93.47, highlighting potential undervaluation based on cash flows. Despite a recent net loss of NOK 383.06 million in Q1 2025, earnings are projected to grow substantially at 30.4% annually over the next three years, surpassing the Norwegian market's growth rate. However, its dividend yield of 5.05% isn't well covered by free cash flows and return on equity remains modestly forecasted at 14.5%. Insights from our recent growth report point to a promising forecast for Lerøy Seafood Group's business outlook. Delve into the full analysis health report here for a deeper understanding of Lerøy Seafood Group. Norconsult Overview: Norconsult ASA offers consultancy services specializing in community planning, engineering design, and architecture across the Nordics and internationally, with a market cap of NOK13.87 billion. Operations: The company's revenue segments include Norway Regions (NOK2.93 billion), Norway Head Office (NOK3.14 billion), Sweden (NOK1.90 billion), Digital and Techno-Garden (NOK1.16 billion), Denmark (NOK891 million), and Renewable Energy (NOK947 million). Estimated Discount To Fair Value: 49% Norconsult ASA is trading at NOK 44.7, significantly below its estimated fair value of NOK 87.62, suggesting undervaluation based on cash flows. Recent earnings show robust growth with net income rising to NOK 257 million from NOK 103 million a year prior. The company secured major contracts like the NRK media house and Bergen Light Rail projects, enhancing its revenue prospects amidst forecasted annual earnings growth of 12.7%, outpacing the Norwegian market's average growth rate. Our growth report here indicates Norconsult may be poised for an improving outlook. Click here and access our complete balance sheet health report to understand the dynamics of Norconsult. Key Takeaways Unlock more gems! Our Undervalued European Stocks Based On Cash Flows screener has unearthed 190 more companies for you to here to unveil our expertly curated list of 193 Undervalued European Stocks Based On Cash Flows. Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments. Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets. Searching for a Fresh Perspective? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ENXTPA:STMPA OB:LSG and OB:NORCO. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
14 minutes ago
- Yahoo
Evotec SE Reports H1 2025 Results: Strong Progress on Strategy Execution
Strategy for sustainable profitable growth progressing as planned with improving revenue mix and ahead-of-plan cost reductions Reporting segment formerly known as Shared R&D renamed to Discovery & Preclinical Development ("D&PD") to better reflect strategic focus Group revenues of € 371.2 m (-5%); D&PD (-11%) continues to see soft demand;Just - Evotec Biologics ("JEB"; +16%) exceeding expectations driven by broadened customer base Key progress in collaborations with Bristol Myers Squibb ("BMS") on targeted protein degradation and neuroscience Evolution of strategic partnership with Sandoz announced on 30 July HAMBURG, DE / / August 13, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) today announced financial results for H1 2025, demonstrating clear progress in the implementation of its new strategy for sustainable and profitable growth; highlighting Just - Evotec Biologics' strong growth as it transitions to an asset-lighter model. Dr Christian Wojczewski, Chief Executive Officer of Evotec, said: "We are firmly on track with the execution of our strategy: Evotec is making meaningful strides toward sustainable and profitable growth. JEB maintained its strong growth trajectory with first half revenues in excess of € 100 m, and the evolution of our strategic partnership with Sandoz is testament to its bright future as a scalable technology provider with a more capital-efficient model. Our base business in D&PD continues to face soft demand, but we see strong progress in core collaborations and are systematically expanding our platform technologies, such as our Molecular Patient Database. I am confident that our unrelenting focus on technology and science leadership will continue to drive tangible impact in the future". Discovery & Preclinical Development impacted by soft market; Just - Evotec Biologics continues strong growth momentum Group revenues decreased by 5.0% to € 371.2 m (6M 2024: € 390.8 m) Total D&PD revenues decreased by 11.0% to € 269.0 m (6M 2024: € 302.4 m) with performance reflecting soft drug discovery market environment and phasing of revenues with Pharma partners; recovery of D&PD market expected as early as 2026 Just - Evotec Biologics revenues increased by 16% to € 102.2 m (6M 2024: € 88.9 m); strong growth with non-Sandoz / non-DoD customers Adjusted Group EBITDA totalled € (1.9) m (6M 2024: € (0.5) m) in-line with expectations due to strong cost control across the business Execution of strategy to refocus and deliver sustainable profitable growth fully on track Cost savings expected to exceed targets announced during the Q1 2025 results call on 06 May 2025 Implementation of strategy and new organization initiated Events after Period-End On 30 July 2025, Evotec announced the signing of a non-binding agreement on the potential sale ofJust - Evotec Biologics EU - which owns the biologics manufacturing facility in Toulouse, France and to grant access to its proprietary platform for integrated development and advanced continuous manufacturing of biologics via a technology license Deal terms include purchase price of the site for around US$ 300 m in cash and additional further technology related consideration, future development revenues, milestones and product royalties Planned transaction validates JEB's end-to-end continuous manufacturing technology and marks milestone in planned transition of JEB to asset-lighter model that better scales and leverages its technology and IP Closing of the planned transaction remains subject to completion of the relevant information and consultation processes with employees and their representatives, final contractual agreements and to meeting regulatory requirements, expected in the fourth quarter Progress in key strategic collaborations Significant progress in strategic protein degradation collaboration with BMS triggering performance-based and program-based payments of in total US$ 75 m Key progress in neuroscience collaboration with BMS triggering a research payment of US$ 20 m Grant awarded from The Gates Foundation ("GF") to support the development of next-generation treatment regimens for tuberculosis ("TB") Evotec joined NURTuRE-AKI consortium, expanding Molecular Patient Database and improving leadership position in the field of kidney disease Evotec welcomed the FDA's "Roadmap to Reducing Animal Testing in Preclinical Safety Studies" which is aligned with Evotec's long-term strategic investment in New Approach Methodologies (NAMs) and its 30+ year commitment to ethics and the principles of 3-Rs (Replacement, Reduction and Refinement) Guidance for full-year 2025 Group revenues expected in a range of € 760 - 800 m (2024: € 797.0 m) R&D expenditures are expected in a range of € 40 - 50 m (2024: € 50.9 m) Adjusted Group EBITDA is expected to reach € 30 - 50 m (2024: € 22.6 m) More detailed information and financial tables are available in the half-year report published on the Evotec website under the following link: Webcast/Conference Call The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The conference call will be held in English. Webcast details Date: Wednesday, 13 August 2025 Time: 2.00 pm CEST (1.00 pm BST, 8.00 am EDT) To join the audio webcast and to access the presentation slides, please register via this link. The on-demand version of the webcast will be available on our website: Financial Publications - Evotec . Conference call details To join via phone, please pre-register via this link. You will then receive a confirmation email with dedicated dial-in details such as telephone number, access code and PIN to access the call. A simultaneous slide presentation for participants dialing in via phone is available under this link. About Evotec SEEvotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure - faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just - Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec's global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. For additional information please go to and follow us on X/Twitter @Evotec and LinkedIn . Forward-looking statementsThis announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. For further information, please contact: Investor Relations Volker BraunEVP Head of Global Investor Relations & SOURCE: Evotec SE View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
